122 related articles for article (PubMed ID: 23961878)
1. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
Fosdick A; Zheng J; Pflanz S; Frey CR; Hesselgesser J; Halcomb RL; Wolfgang G; Tumas DB
J Pharmacol Exp Ther; 2014 Jan; 348(1):96-105. PubMed ID: 24133297
[TBL] [Abstract][Full Text] [Related]
4. Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
Tran TD; Pryde DC; Jones P; Adam FM; Benson N; Bish G; Calo F; Ciaramella G; Dixon R; Duckworth J; Fox DN; Hay DA; Hitchin J; Horscroft N; Howard M; Gardner I; Jones HM; Laxton C; Parkinson T; Parsons G; Proctor K; Smith MC; Smith N; Thomas A
Bioorg Med Chem Lett; 2011 Apr; 21(8):2389-93. PubMed ID: 21419626
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a highly potent series of TLR7 agonists.
Jones P; Pryde DC; Tran TD; Adam FM; Bish G; Calo F; Ciaramella G; Dixon R; Duckworth J; Fox DN; Hay DA; Hitchin J; Horscroft N; Howard M; Laxton C; Parkinson T; Parsons G; Proctor K; Smith MC; Smith N; Thomas A
Bioorg Med Chem Lett; 2011 Oct; 21(19):5939-43. PubMed ID: 21885277
[TBL] [Abstract][Full Text] [Related]
6. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
[TBL] [Abstract][Full Text] [Related]
7. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.
Li L; Barry V; Daffis S; Niu C; Huntzicker E; French DM; Mikaelian I; Lanford RE; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):912-921. PubMed ID: 29247724
[TBL] [Abstract][Full Text] [Related]
8. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
[TBL] [Abstract][Full Text] [Related]
9. 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.
Embrechts W; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Pande V; Pille G; Amssoms K; Smyej I; Dhuyvetter D; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thone T; De Pooter D; Fanning G; Jonckers THM; Horton H; Raboisson P; McGowan D
J Med Chem; 2018 Jul; 61(14):6236-6246. PubMed ID: 29965759
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Lopatin U; Wolfgang G; Tumas D; Frey CR; Ohmstede C; Hesselgesser J; Kearney B; Moorehead L; Subramanian GM; McHutchison JG
Antivir Ther; 2013; 18(3):409-18. PubMed ID: 23416308
[TBL] [Abstract][Full Text] [Related]
11. Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
McGowan DC; Herschke F; Pauwels F; Stoops B; Smyej I; Last S; Pieters S; Embrechts W; Khamlichi MD; Thoné T; Van Schoubroeck B; Mostmans W; Wuyts D; Verstappen D; Scholliers A; De Pooter D; Dhuyvetter D; Borghys H; Tuefferd M; Arnoult E; Hong J; Fanning G; Bollekens J; Urmaliya V; Teisman A; Horton H; Jonckers THM; Raboisson P
J Med Chem; 2017 Jul; 60(14):6137-6151. PubMed ID: 28671847
[TBL] [Abstract][Full Text] [Related]
12. Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.
McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Scholliers A; Thoné T; Van Schoubroeck B; De Pooter D; Mostmans W; Khamlichi MD; Embrechts W; Dhuyvetter D; Smyej I; Arnoult E; Demin S; Borghys H; Fanning G; Vlach J; Raboisson P
J Med Chem; 2016 Sep; 59(17):7936-49. PubMed ID: 27513093
[TBL] [Abstract][Full Text] [Related]
13. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Mackman RL; Mish M; Chin G; Perry JK; Appleby T; Aktoudianakis V; Metobo S; Pyun P; Niu C; Daffis S; Yu H; Zheng J; Villasenor AG; Zablocki J; Chamberlain J; Jin H; Lee G; Suekawa-Pirrone K; Santos R; Delaney WE; Fletcher SP
J Med Chem; 2020 Sep; 63(18):10188-10203. PubMed ID: 32407112
[TBL] [Abstract][Full Text] [Related]
14. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
Thomas A; Laxton C; Rodman J; Myangar N; Horscroft N; Parkinson T
Antimicrob Agents Chemother; 2007 Aug; 51(8):2969-78. PubMed ID: 17548497
[TBL] [Abstract][Full Text] [Related]
15. Molecular Determinants of GS-9620-Dependent TLR7 Activation.
Rebbapragada I; Birkus G; Perry J; Xing W; Kwon H; Pflanz S
PLoS One; 2016; 11(1):e0146835. PubMed ID: 26784926
[TBL] [Abstract][Full Text] [Related]
16. Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.
Pieters S; McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Embrechts W; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thoné T; De Pooter D; Fanning G; Rosauro ML; Khamlichi MD; Houpis I; Arnoult E; Jonckers THM; Raboisson P
Bioorg Med Chem Lett; 2018 Feb; 28(4):711-719. PubMed ID: 29366653
[TBL] [Abstract][Full Text] [Related]
17. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
Boonstra A; Liu BS; Groothuismink ZM; Bergmann JF; de Bruijne J; Hotho DM; Hansen BE; van Vliet AA; van de Wetering de Rooij J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Reesink HW; de Knegt RJ; Janssen HL
Antivir Ther; 2012; 17(4):657-67. PubMed ID: 22301364
[TBL] [Abstract][Full Text] [Related]
18. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
[TBL] [Abstract][Full Text] [Related]
19. TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation.
Enosi Tuipulotu D; Netzler NE; Lun JH; Mackenzie JM; White PA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530841
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
